4//SEC Filing
ONYX PHARMACEUTICALS INC 4
Accession 0001181431-13-052519
CIK 0001012140operating
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 9:18 PM ET
Size
23.0 KB
Accession
0001181431-13-052519
Insider Transaction Report
Form 4
Fust Matthew K
Chief Financial Officer
Transactions
- Disposition from Tender
Common Stock
2013-10-01$125.00/sh−9,153$1,144,125→ 31,150 total - Disposition to Issuer
Stock Options
2013-10-01−41,450→ 0 totalExercise: $34.48From: 2010-01-05Exp: 2019-01-05→ Common Stock (41,450 underlying) - Disposition to Issuer
Stock Options
2013-10-01−3,019→ 0 totalExercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (3,019 underlying) - Disposition to Issuer
Common Stock
2013-10-01$125.00/sh−31,150$3,893,750→ 0 total - Disposition to Issuer
Stock Options
2013-10-01−3,904→ 0 totalExercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (3,904 underlying) - Disposition to Issuer
Stock Options
2013-10-01−41,596→ 0 totalExercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (41,596 underlying) - Disposition to Issuer
Stock Options
2013-10-01−38,981→ 0 totalExercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (38,981 underlying) - Disposition to Issuer
Stock Options
2013-10-01−2,856→ 0 totalExercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (2,856 underlying) - Disposition to Issuer
Stock Options
2013-10-01−22,600→ 0 totalExercise: $88.86From: 2014-03-28Exp: 2023-03-28→ Common Stock (22,600 underlying) - Disposition to Issuer
Stock Options
2013-10-01−43,044→ 0 totalExercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (43,044 underlying)
Footnotes (2)
- [F1]These restricted stock awards were cancelled at the effective time of the merger (the "Merger") pursuant to the Agreement and Plan of Merger, dated August 24, 2013, by and among Onyx Pharmaceuticals, Inc. ("Onyx"), Amgen Inc. and Arena Acquisition Company (the "Merger Agreement") in exchange for an aggregate cash payment equal to the number of shares of Onyx's common stock underlying such restricted stock awards multiplied by the per share purchase price of $125.00. Reflects the forfeiture of 8,575 performance based restricted stock units.
- [F2]Represents options to purchase Onyx's common stock that were subject to vesting over time but were cancelled in the Merger in exchange for a cash payment in the amount by which the per share purchase price of $125.00 exceeded the exercise price of the option as of the effective time of the Merger.
Documents
Issuer
ONYX PHARMACEUTICALS INC
CIK 0001012140
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001012140
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 9:18 PM ET
- Size
- 23.0 KB